Drug Type Biosimilar, Monoclonal antibody |
Synonyms Tocilizumab Biosimilar (Taizhou Mabtech Pharmaceutical Co. Ltd.), 托珠单抗生物类似药(Taizhou Mabtech Pharmaceutical Co. Ltd.), CMAB-806 + [1] |
Target |
Mechanism IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (16 Oct 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rheumatoid Arthritis | CN | 16 Oct 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Juvenile Idiopathic Arthritis | Phase 1 | CN | 19 Sep 2018 |